

Existing Chemical Hazard Assessment Report



Australian Government
Department of Health and Ageing
NICNAS

Dimethyl Phthalate

June 2008

© Commonwealth of Australia 2008

This work is copyright. You may download, display, print and reproduce this material in unaltered form only (retaining this notice) for your personal, non-commercial use or use within your organisation. Apart from any use as permitted under the Copyright Act 1968, all other rights are reserved. Requests and inquiries concerning reproduction and rights should be addressed to Commonwealth Copyright Administration, Attorney General's Department, Robert Garran Offices, National Circuit, Barton ACT 2600 or posted at <http://www.ag.gov.au/cca>

Preface

This report was compiled under the National Industrial Chemicals Notification and Assessment Scheme (NICNAS). This Scheme was established by the *Industrial Chemicals (Notification and Assessment) Act 1989* (Cwlth) (the Act), which came into operation on 17 July 1990.

The principal aim of NICNAS is to aid in the protection of people at work, the public and the environment from the harmful effects of industrial chemicals.

NICNAS assessments are carried out in conjunction with the Department of the Environment, Water, Heritage and the Arts, which carry out the environmental assessment for NICNAS. NICNAS has two major programs: the assessment of the health and environmental effects of new industrial chemicals prior to importation or manufacture; and the other focussing on the assessment of chemicals already in use in Australia in response to specific concerns about their health/or environmental effects.

There is an established mechanism within NICNAS for prioritising and assessing the many thousands of existing chemicals in use in Australia.

For the purposes of Section 78(1) of the Act, copies of assessment reports for New and Existing Chemical assessments are freely available from the web (www.nicnas.gov.au). Summary Reports are published in the *Commonwealth Chemical Gazette* (<http://www.nicnas.gov.au/publications/#gazette>), and are available to the public on line at www.nicnas.gov.au.

Copies of this report and other NICNAS reports are available on the NICNAS website. Hardcopies are available from NICNAS at the following address:

GPO Box 58
Sydney NSW 2001
AUSTRALIA
Attention: Office Manager
Tel: +61 (02) 8577 8800
Freecall: 1800 638 528
Fax: +61 (02) 8577 8888
Email: info@nicnas.gov.au

Other information about NICNAS (also available on request) includes:

- NICNAS Annual Reports.
- NICNAS Service Charter.
- Brochure on NICNAS Registration.

More information on NICNAS can be found at the NICNAS web site:

<http://www.nicnas.gov.au>

Overview

This review of dimethyl phthalate (DMP) is a health hazard assessment only. For this assessment, a review by Cosmetic Ingredient Review was the main source of information. Information was also obtained from the British Industrial Biological Research Association (BIBRA) Toxicity Profile and from the International Uniform Chemical Information Database (IUCLID) dataset on DMP. These information sources were supplemented with literature surveys conducted up to September 2006.

Internationally, DMP is used in cosmetics as a fragrance ingredient, in hair sprays, hair conditioners, face powders and foundations, bath soaps and detergents, deodorants and aftershave lotions. Non-cosmetic uses include as solvents and plasticisers for nitrocellulose, cellulose acetate and cellulose acetate-butyrate compositions. DMP is used in explosives, printing inks, paper coatings and adhesives and as a fabric treatment. DMP is also used in insecticides and insect repellents.

In Australia, DMP is imported as finished products or mixtures and as a raw chemical for local manufacture. DMP is used industrially as automotive parts, encapsulation of electrical wiring, mining and construction, fabrication of fibreglass, paints, nitrocellulose, cellulose acetates and rubber. Downstream products include adhesives, putty hardeners, paints and coatings, plastic articles, children's toys, and fragrance bases for household cleaning and cosmetic products. DMP is also used by various institutions and laboratories for biotechnological and pharmaceutical research.

Structurally, phthalate esters are characterized by a diester structure consisting of a benzenedicarboxylic acid head group linked to two ester side chains. DMP possesses 2 ester side chains each of one carbon (C1).

DMP is absorbed via the gastrointestinal tract and via the skin. Following absorption, DMP was distributed to multiple organs but rapidly cleared, with no accumulation. In rats over 7 days, approximately 6% per day of dermally applied DMP was absorbed and recovered in urine and faeces. In vitro, human epidermis was an order of magnitude less permeable to DMP than rat epidermis. Following oral administration in rats, the main metabolites were monomethyl phthalate (MMP) and free phthalic acid.

DMP was of low acute oral and dermal toxicity in rats, mice, rabbits and guinea pigs. Data were insufficient to determine the potential for acute inhalation toxicity.

DMP produces minimal skin irritant effects in animals and humans. It induces minimal eye irritation in rabbits. A single human case report noted eye irritation following contact with DMP. Available data from animals and humans suggest that DMP was not a skin sensitiser.

In repeat dose animal studies, the kidney appeared to be the primary target organ, with effects on nervous system, lungs, liver and testes also reported. A NOAEL of 1000 mg/kg bw/d and a LOAEL of 2000 mg/kg bw/d based on reduced weight gains were determined in a 2-year feeding study in rats. A repeat dose NOAEL of 1200 mg/kg bw/d and a LOAEL of 2400 mg/kg bw/d based on nephritis seen at this dose and above were determined from a 90-day dermal study in rabbits.

DMP showed equivocal evidence in both in vitro and in vivo genotoxicity studies. Overall, based on all data available and on a weight-of-evidence basis, DMP is unlikely to be genotoxic.

A 2-year rat feeding study did not report any neoplastic endpoints at concentrations of DMP up to 4000 mg/kg bw/d. A one-year initiation/promotion study with dermal applications of 3000 mg/kg bw/d DMP in mice showed no evidence of carcinogenic initiation/promotion potential. A single mammalian cell transformation assay was negative. Overall, data were inadequate to determine the carcinogenic potential of DMP.

The human and animal data were insufficient to assess adequately the effects of DMP on fertility. A single study reported effects on development from intraperitoneal injection of DMP in rats. In contrast, other studies (oral and dermal) reported no effects. Overall, data indicated that gestational exposure to DMP in rats or mice above doses likely to be maternally toxic are unlikely to have developmental consequences. The NOAEL for developmental effects in a rat oral feeding study was 3570 mg/kg bw/d (the highest dose tested).

Table of Contents

PREFACE	iii
OVERVIEW	iv
ACRONYMS AND ABBREVIATIONS	viii
1. INTRODUCTION	1
2. IDENTITY	2
2.1 Identification of the substance	2
2.2 Physico-chemical properties	2
3. USES	3
4. HUMAN HEALTH HAZARD	4
4.1 Toxicokinetics	4
4.2 Acute toxicity	5
4.3 Irritation	6
4.3.1 Skin irritation	6
4.3.2 Eye irritation	6
4.3.3 Respiratory irritation	7
4.4 Sensitisation	7
4.5 Repeated dose toxicity	8
4.6 Genetic toxicity	9
4.7 Carcinogenicity	11
4.8 Reproductive toxicity	11
4.8.1 Human studies	12
4.8.2 Repeat dose toxicity studies	12
4.8.3 Prenatal developmental toxicity studies	13
4.8.4 Developmental/postnatal toxicity studies	14
4.8.5 Mode of action	14
4.8.6 Conclusion	14
5. HAZARD CHARACTERISATION	15
6. HUMAN HEALTH HAZARD SUMMARY TABLE	17
REFERENCES	19

Acronyms and Abbreviations

AGD	anogenital distance
AGI	anogenital index
BBP	butylbenzyl phthalate
bw	body weight
C	Celsius
CAS	Chemical Abstracts Service
CHO	Chinese hamster ovary
d	day
DBP	dibutyl phthalate
DEHP	diethylhexyl phthalate
DEP	diethyl phthalate
DINP	diisononyl phthalate
DMP	dimethyl phthalate
DOTP	dioctyl terephthalate
g	gram
GD	gestation day
GLP	good laboratory practice
h	hour
ip	intraperitoneal
IUCLID	International Uniform Chemical Information Database
kg	kilogram
kPa	kilopascals
L	litre
LC50	median lethal concentration
LD50	median lethal dose
LH	luteinizing hormone
LOAEL	lowest-observed-adverse-effect level
M	moles
mg	milligram
mL	millilitre
MCF-7	human breast adenocarcinoma cell line
mmol	millimole
MMP	monomethyl phthalate

NICNAS	National Industrial Chemicals Notification and Assessment Scheme
NOAEL	no-observed-adverse-effect level
OECD	Organisation for Economic Cooperation and Development
PND	post natal day
ppm	parts per million
SCE	sister chromatid exchange
μ	micro

1. Introduction

This review of dimethyl phthalate (DMP) is a health hazard assessment only. For this assessment, a review by Cosmetic Ingredient Review (CIR, 2002) was the main source of information. Information was also obtained from BIBRA (1994) and from the European Chemicals Bureau IUCLID Dataset on DMP (ECB, 2000). The IUCLID dataset has not undergone evaluation by the European Commission. These information sources were supplemented with relevant studies from more recent literature surveys conducted up to September 2006.

Information on Australian uses was compiled from data supplied by industry in 2004 and 2006.



References not marked with an asterisk were examined for the purposes of this assessment. References not examined but quoted from the key reviews as secondary citations are also noted in this assessment and marked with an asterisk.

Hazard information from this assessment is published also in the form of a hazard compendium providing a comparative analysis of key toxicity endpoints for 24 *ortho*-phthalate esters (NICNAS, 2008).

2. Identity

2.1 Identification of the substance

CAS Number:	131-11-3
Chemical Name:	1,2-Benzenedicarboxylic acid, dimethyl ester
Common Name:	Dimethyl phthalate (DMP)
Molecular Formula:	C ₁₀ H ₁₀ O ₄
Structural Formula:	



Molecular Weight:	194.19
Synonyms:	Dimethyl-1,2-benzenedicarboxylate, Phthalic acid dimethyl ester, Dimethyl benzeneorthodicarboxylate, Dimethyl o-phthalate
Purity/Impurities/Additives:	None identified

2.2 Physico-chemical properties

Table 1: Summary of physico-chemical properties

Property	Value
Physical state	Colourless oily liquid
Melting point	5.5°C
Boiling point	284°C
Density	1190 kg/m ³ (20°C)
Vapour pressure	8.0 x 10 ⁻⁴ (20°C)
Water solubility	4.3 g/L (20°C)
Partition coefficient n-octanol/water (log Kow)	1.47 - 2.12 (temperature not specified)
Henry's law constant	Not available
Flash point	146°C

Source: ECB (2000), IPCS (2005)

3. Uses

Internationally, DMP is used in cosmetics as a fragrance ingredient, in hair sprays, hair conditioners, face powders and foundations, bath soaps and detergents, deodorants and aftershave lotions. Non-cosmetic uses include as solvents and plasticisers for nitrocellulose, cellulose acetate and cellulose acetate-butyrate compositions. DMP is used in explosives, printing inks, paper coatings and adhesives and as a fabric treatment. DMP is also used in insecticides and insect repellents (CIR, 2002).

In Australia, DMP is imported as finished products or mixtures and as a raw chemical for local manufacture. DMP is used industrially as automotive parts, encapsulation of electrical wiring, mining and construction (e.g. minerals separation chemicals, insulation coatings and specialised surface protection coatings such as on aluminium extrusions) and fabrication of fibreglass, paints, nitrocellulose, cellulose acetates and rubber. Downstream products include adhesives, putty hardeners, paints and coatings, plastic articles, children's toys, and fragrance bases for household cleaning and cosmetic products. DMP is also used by various institutions and laboratories for biotechnological and pharmaceutical research.

4. Human Health Hazard

4.1 Toxicokinetics

Previous evaluations

The following data are obtained from CIR (2002).

DMP is readily absorbed from the gastrointestinal system primarily as the monoester (White et al., 1980*). It is also absorbed via the skin. Following dermal absorption DMP is distributed to a variety of tissues and excreted with little retained. In rats, a relatively constant 6% of an applied dermal dose of DMP was recovered in the urine and faeces per day over 7 days (Elsisi et al., 1989). After 7 days, up to 40% of the dose was recovered from urine and faeces with 19% remaining at the dose site (Elsisi et al., 1989).

In vitro studies provided values of 2.5 to 4 $\mu\text{g}/\text{cm}^2/\text{h}$ for absorption of DMP through human epidermis and 40 to 50 $\mu\text{g}/\text{cm}^2/\text{h}$ through rat epidermis (Scott et al., 1987; Hilton et al., 1994). Dermal absorption of DMP in rat was highly solvent dependent, with up to a 10-fold difference between different solvents. Solvent effects were not as pronounced in human skin (Hilton et al., 1994). Reifenrath et al. (1989*) reported a peak rate of 3 $\mu\text{g}/\text{cm}^2/\text{h}$ for pig skin.

Following oral administration in rats, the primary metabolites for DMP in urine were the monoester monomethyl phthalate (MMP) (78%) with some free phthalic acid (14.4%) and unchanged DMP (8.1%) (Albro & Moore, 1974*). In vitro, the rate of metabolism of DMP by rat epidermal homogenates was approximately 1.5% that of liver homogenates (Kozumbo et al., 1982*). Methanol and formaldehyde have been reported as in vivo and in vitro metabolites of DMP (Kozumbo & Rubin, 1991*; Surina et al, 1984*).

Data not reported in previous evaluations

No data.

Conclusion

DMP is absorbed via the gastrointestinal tract and via the skin. In rats, 6% per day of dermally applied DMP was recovered in urine and faeces over 7 days. In vitro, human epidermis was an order of magnitude less permeable to DMP than rat epidermis. Following absorption, DMP is distributed to multiple organs but rapidly cleared, with no accumulation.

Following oral administration, the main DMP metabolites were the monoester (MMP) (78%), with free phthalic acid and unchanged DMP comprising the remainder of the eliminated dose. Methanol and formaldehyde have also been identified as metabolites in vivo and in vitro.

4.2 Acute toxicity

Previous evaluations

Table 2. Summary of acute toxicity studies

Study	Species	Results (LD50/LC50)	References
Oral	Rat	6.9 mL/kg bw (8.2 g/kg bw) [#]	Draize et al. (1948)*
	Rabbit	4.4 mL/kg bw (5.2 g/kg bw) [#]	Draize et al. (1948)*
	Guinea pig	2.4 mL/kg bw (2.9 g/kg bw) [#]	Draize et al. (1948)*
	Chick	8.5 mL/kg bw (10.1 g/kg bw) [#]	Draize et al. (1948)*
	Mouse	7.2 mL/kg bw (8.6 g/kg bw) [#]	Draize et al. (1948)*
	Mouse	6.3 g/kg bw	Plasterer et al. (1985)
Intraperitoneal (ip)	Mouse	18.8 mmol/kg bw (3.7 g/kg bw) [#]	Karel et al. (1947)*
	Mouse	3.98 g/kg bw	Lawrence et al. (1975)*
	Rat	3.38 mL/kg bw (4.0 g/kg bw) [#]	Singh et al. (1972)

Source: CIR (2002); [#] - calculated

In addition to the above data from CIR (2002), the IUCLID for DMP contains a compilation of summarised acute toxicity data not evaluated by the European Commission (ECB, 2000). In the only study noted as being conducted to Good Laboratory Practice (GLP), the oral LD50 for DMP in rats was 5740 mg/kg bw for males and 4390 mg/kg bw for females (Union Carbide Corp, 1987*). Dermal LD50 values noted by ECB (2000) range from > 4800 mg/kg bw in guinea pigs to 38000 mg/kg bw in rats.

No deaths resulted in rats (number unspecified) from acute inhalation of a saturated vapour (no details of concentration) of DMP for 6 hours a day (Levinskas, 1973*). Cats survived a 6.5 hour exposure to a DMP mist of 2.0 mg/L but one of two cats died when the concentration was increased to 10.2 mg/L (Levinskas, 1973*).

Data not reported in previous evaluations

No additional data were available.

Conclusion

DMP is of low acute oral and dermal toxicity. The oral LD50 was 4390-8200 mg/kg bw/d (rats) and the dermal LD50 was 38000 mg/kg bw (rats) and > 4800 mg/kg bw (guinea pigs). Data are insufficient to determine the potential for acute inhalation toxicity.

4.3 Irritation

4.3.1 Skin irritation

Previous evaluations

Irritation and ulceration were reported from a one-year dermal initiation/promotion study following daily application of 0.1 mL of DMP to unoccluded mouse skin (5 days per week) (NTP, 1995). However, the effects of vehicle could not be discounted in this study design.

DMP was reported as not irritating in rabbits in a Draize test following application of up to 4 mL/kg bw to occluded and unoccluded (intact and abraded) skin (Draize et al., 1948*). DMP was not irritating except in molting areas with 0.5 mL applied to clipped, intact and abraded skin of 3 rabbits for 24 hours (Lehman, 1955).

No skin irritation was reported when DMP was applied at doses up to 4.0 mL/kg per day for 90 days to the clipped intact skin of rabbits. However, DMP was irritating to the penile mucosa (Lehman, 1955). No significant irritation was reported in another short-term dermal study of 25 applications of 4.8 g/kg bw/d for 33 days under occlusion (Dow Chemical, 1946*).

Dupont (1970*) reported that 0.05 mL DMP applied to intact skin of male albino guinea pigs produced no primary irritation. Also, 9 similar applications of DMP to abraded skin in guinea pigs over a 3 week period produced no oedema or erythema (Dupont, 1970*).

Human studies

Closed patch tests provoked irritant reactions in 3 of 190 subjects (equivocal in a further 6) tested with 0.5% DMP in a cream base (Takenaka et al., 1970*). In another study, application of 50% DMP (in ethanol) to the face of 10 volunteers produced no visible signs of irritation (Frosch & Kligman, 1977*). No further details were provided for these studies.

Data not reported in previous evaluations

No data.

Conclusion

None of the studies were conducted according to recognised guidelines. Available data suggests DMP causes minimal skin irritation in rabbits and guinea pigs. Similar minimal effects are suggested in humans.

4.3.2 Eye irritation

Previous evaluations

Application of up to 0.5 mL of undiluted DMP to the rabbit eye produced slight irritation (Draize et al., 1944*; Carpenter & Smyth, 1946*; Lawrence et al., 1975*).

Human studies

McLaughlin (1946)* reported that human contact with undiluted DMP produced corneal damage, which following medical treatment healed within 48 hours with no loss of vision. No further details were provided.

Data not reported in previous evaluations

No data.

Conclusion

None of the studies were conducted according to recognised guidelines. Limited data suggest DMP induces minimal eye irritation in rabbits. A single case report suggested DMP may induce eye irritation in humans.

4.3.3 Respiratory irritation

Previous evaluations

No data.

Data not reported in previous evaluations

No data.

4.4 Sensitisation

Previous evaluations

No evidence of sensitisation was seen in rabbits receiving daily skin applications of DMP at doses of up to 4 mL/kg per day for 90 days (Lehman, 1955).

No signs of oedema or erythema were seen in guinea pigs when challenged with DMP on abraded or intact skin, 2 weeks after a 3-week period of 9 dermal applications of 0.05 mL DMP (Dupont, 1970*).

Human studies

Only one positive reaction was observed in 1532 dermatitis patients patch tested (48 hours under a “closed” patch) with a mixture of 2% DMP, 2% DEP and 2% DBP in petrolatum (Schulsiner & Mollgaard, 1980*). A positive patch test response to DMP (5% in petrolatum) was reported in a 71-year old woman (with contact dermatitis) in a separate case report (Oliwiecki et al., 1991*).

Patch testing of 16 subjects (8 per sex) did not reveal any positive responses to DMP when challenged for 2 days following a 2-week ‘rest period’ after 6 days of continuous dermal application (Dupont, 1982*).

Kanerva et al. (1999) reported results from patch testing of 310 patients referred to an occupational dermatology clinic over a 6 year period. None of the patients tested with 5% DMP under occlusion for 2 days exhibited allergic reactions.

Data not reported in previous evaluations

No data.

Conclusion

Available animal and human studies indicate that DMP does not cause skin sensitisation.

4.5 Repeated dose toxicity

Previous evaluations

Oral

In a Sprague-Dawley rat study, administration (by gavage) of 1400 mg/kg bw/d DMP for 4 days induced no significant changes in body weight, testes weight, testes microscopic appearance or in urinary zinc excretion (Cater et al., 1977*; Foster et al., 1980*; Gangolli, 1982*).

DMP administered in diet at 2% (approximately 2000 mg/kg bw/d) to 10 young male JCL:Wistar rats for 7 days induced statistically significant elevations in liver weights (approx. 17%) compared to 20 control animals (Oishi & Hiraga, 1980). Zinc levels in the liver and testes were unaffected, but the concentration of testosterone in the serum and testes was decreased by approximately 50 to 70%.

In 14-day (gavage) and 21-day (feeding) studies, DMP at doses of 1000 and 500 mg/kg bw/d, respectively, did not induce hepatomegaly in rats (Lake et al., 1978*; Bell et al., 1978*). In a 21-day study in Sprague-Dawley rats, no effects on growth or liver weight were reported. Reductions in cholesterol and total lipids were reported in liver, but not in serum (ECB 2000).

In a 2-year rat study (10 females/dose), DMP in the diet at 2, 4 and 8% (approximately 1000, 2000 and 4000 mg/kg bw/d) induced chronic nephritis in the high dose group. Exposure to 4% and 8% had a slight but significant effect on growth. A NOAEL of 1000 mg/kg bw/d was determined for this study based on reduced body weight gain at 2000 mg/kg bw/d (Lehman, 1955).

Dermal

A slight reduction in haematocrit and testes weights was reported in rabbits following dermal application of DMP (4800 mg/kg bw/d for 33 days). No histological changes were seen at termination (Dow Chemical, 1946*).

In a 3-month rat (males only) study (application doses of 200, 1250, 2000 mg/kg bw/d), nervous system and renal function changes were noted at 1250 and 2000 mg/kg bw/d (Timofievskaya et al., 1976*).

In a 90-day (dermal) study in rabbits, daily DMP applications of 600-4800 mg/kg bw/d produced slight renal damage (nephritis) at 2400 mg/kg bw/d, weight loss, pulmonary oedema and kidney and liver damage at 4800 mg/kg bw/d. A NOAEL of 1200 mg/kg bw/d was determined for this study, based on nephritis seen at 2400 mg/kg bw/d and above (Draize et al., 1944*; 1948*; Lehman, 1955).

In a one-year carcinogenicity study (see section 4.7), no gross or histopathologic changes or changes in body weight or survival indices were reported in male Swiss

CD-1 mice following 5 applications per week of 0.1 mL DMP (~3000 mg/kg bw) (NTP, 1995).

Inhalation

In a 4-month rat study, exposure to concentrations of 0.68 and 1.84 mg/m³ DMP for 4 h/d resulted in changes in respiratory rate, decreased haemoglobin, altered red blood cell count, reduced weight gain, disturbed diuresis, altered chloride in urine and increased clearance of hippuric acid at the high dose (Timofievskaya et al., 1974*).

Data not reported in previous evaluations

No additional data were available.

Conclusion

In general, limited data are available from repeat dose studies of DMP in animals. In oral studies in rats, high doses (above 2000 mg/kg bw/d) induced kidney effects (nephritis) and liver effects (weight increases). The highest dose (4800 mg/kg bw/d) induced weight loss, pulmonary oedema and kidney and liver damage. In separate studies, increases in liver weight and decreases in liver cholesterol and total lipids were reported.

From a limited 2-year rat oral feeding study, a NOAEL of 1000 mg/kg bw/d was reported. The LOAEL was 2000 mg/kg bw/d based on reduced body weight gains.

A single available study of inhalation exposure was inadequate to establish conclusions on repeated inhalation toxicity.

In repeat dose dermal studies in rats and rabbits, the kidney appears to be the primary target organ with effects on nervous system (rat), lungs and testes (rabbit) also reported. The sub-chronic repeat dose (dermal) NOAEL in rabbits from a 90-day study was reported as 1200 mg/kg bw/d, based on nephritis seen at 2400 mg/kg bw/d and above.

4.6 Genetic toxicity

Previous evaluations

In vitro

In a modified Ames test (with histidine and biotin incorporation), DMP produced a positive dose-related (500 to 4000 µg/plate) mutagenic response in *S. typhimurium* strain TA100 without metabolic activation, but negative with and without metabolic activation with *S. typhimurium* strain TA98 (Kozumbo et al., 1982). DMP was also tested by Agarwal et al. (1985) in *S. typhimurium* strains TA98, TA100, TA1535, TA1537, TA1538 and TA2637, at doses up to 2000 µg/plate, both with and without metabolic activation. DMP produced a significant increase in TA1535 revertant colonies at 500-750 µg/plate. This effect was eliminated when S9 was added to the mix.

In a liquid suspension assay (measuring 8-azaguanine resistance), DMP was weakly positive in *S. typhimurium* strains TA 100 without metabolic activation. A dose-related increase in revertant frequency (mutagenic response) was seen from 5 to 10

mM DMP. Increasing the concentration of S9 by five-fold completely blocked the mutagenic response (Seed, 1982).

NTP (1995) reported that DMP (33-6666 µg/plate) was negative in *S. typhimurium* strains TA98, TA100, TA1535, and TA1537 both with and without metabolic activation. Neither MMP (main in vitro metabolite) nor rat urine (from animals treated by ip injection of 0.02 µg /kg DMP) were mutagenic in Ames or *E. coli* mutation assays (Kozumbo & Rubin, 1991).

DMP induced sister chromatid exchange (SCE) in Chinese hamster ovary (CHO) cells, only with metabolic activation, but did not induce chromosome aberrations (NTP 1995). Similarly, DMP at doses up to 0.25 mg/mL had no effect on chromatid aberrations in human leukocyte cultures (no further details) (Tsuchiya & Hattori, 1976*).

In a mouse lymphoma assay (L5178Y cells), substantial increases in both “total mutant colonies” and “mutant frequency” values were observed at concentrations up to 3.7 mM DMP, with metabolic activation. However, the results were considered inconclusive by the authors who attributed the positive results to the presence of aldehyde metabolites (Barber et al., 2000).

In vivo

Brief summaries of in vivo cytogenetic assays were reported in the IUCLID for DMP (ECB, 2002). Equivocal results were noted for hepatocyte chromosome aberrations in the liver of rats from dermal applications of DMP at 1.25 g/kg bw/d for 1 month (Yurchenko, 1977*).

No increased frequencies were seen in bone marrow cell metaphases or chromatid exchanges in mice given an ip injection of 1.4 g/kg DMP (Yurchenko, 1977*).

DMP was also reported to be negative in mouse (C57 B1) dominant lethal assays, with animals dosed by ip injection (once only) or dermally 5 days/week for 2 months. For both tests the dose was 1250 mg/kg bw/d. No further details were available (Yurchenko, 1977*).

Data not reported in previous evaluations

Kubo et al. (2002) found DMP to be negative (with and without metabolic activation) in a modified Ames test in *S. typhimurium* strains TA98 and 100 at up to 100 nM DMP per plate.

Conclusion

Equivocal evidence exists for the mutagenic activity of DMP in *S. typhimurium*. Results appear dependent on the assay protocol, with TA100 and TA1535 being the only strains testing positive in some, but not all, assays. Metabolic activation inhibited these positive responses. Positive results were reported in vitro in hamster SCE but DMP tested negative in these cells for chromosomal aberrations. No effects were reported for chromatid aberrations in human leukocyte cultures. DMP tested positive in mouse lymphoma assays with metabolic activation, however, the authors interpreted these results as possible false positives.

In vivo, equivocal results were noted for hepatocyte chromosome aberrations following dermal applications and negative results were noted for chromosome

damage in bone marrow following ip injections and in dominant lethal tests following ip or dermal applications.

Overall, weight-of-evidence suggests that DMP is non-genotoxic.

4.7 Carcinogenicity

Previous evaluations

No human data on carcinogenicity were available for DMP.

In an in vitro mammalian cell transformation assay, DMP was tested on Balb/c-3T3 mouse cells (Barber et al., 2000). With an exposure period of 72 h and incubation over 4 weeks DMP did not induce statistically significant increases in transforming activity with concentrations up to 0.93µL/mL.

No in vivo carcinogenicity studies have been undertaken for DMP in laboratory animals. A 2-year chronic toxicity rat feed study (10 females/dose), with concentrations of DMP up to 4000 mg/kg bw/d did not report any neoplastic lesions, however details of the endpoints evaluated and organs studied were not available. No details of histological examinations were provided (Lehman, 1955).

In a one-year initiation/promotion study, DMP (3000 mg/kg bw/d) did not initiate (with the promoter 12-*O*-Tetradecanoylphorbol-13-acetate (TPA)) or promote (with the initiator 7,12-Dimethylbenz(a)anthracene (DMBA)) skin carcinogenesis in male Swiss CD-1 mice (50 per group). Mean body weights of mice treated with DMP were similar to vehicle controls throughout the study. A positive control response (squamous cell papillomas and carcinomas) was induced by DMBA and TPA in conjunction with acetone vehicle. In contrast, no animals treated with DMP with acetone or acetone vehicle alone showed any incidence of these neoplasms. The report concluded no evidence of tumour initiating or promoting activity of DMP (NTP, 1995).

Data not reported in previous evaluations

No additional data were available.

Conclusion

Data are inadequate to determine the carcinogenic potential of DMP.

4.8 Reproductive toxicity

Traditional hazard assessments consider effects on fertility separate from developmental toxicity. Fertility is tested by exposing sexually mature adults to a chemical and examining the effects on reproductive capacity. Developmental toxicity is studied by exposing pregnant dams and looking for effects in the foetuses. Chemicals that affect the developing reproductive system following prenatal exposure may also affect sexual maturation or functional reproductive disorders that are only apparent at maturity. Developmental toxicity can therefore lead to effects on fertility and the two endpoints cannot be clearly distinguished.

In this hazard assessment, data are presented on the basis of test procedure. Test procedures include repeat dose toxicity studies that dose adult animals for varying

durations, 2-generation studies, prenatal developmental toxicity studies (only the dam is dosed, study ends before parturition) and postnatal developmental toxicity studies (dam is dosed during gestation and allowed to litter, study ends during weaning). The effects on fertility (as adults) and development (as foetuses) are then discussed separately.

4.8.1 Human studies

Previous evaluations

Reduced fertility was reportedly seen in a group of women occupationally exposed to phthalates, including DMP (Aldyreva et al., 1975*). The study was considered inadequate on a number of aspects, including the lack of information on the selection of the unexposed control group and details of exposures to other substances and therefore no conclusions could be drawn.

Colon et al. (2000) found DMP (and other phthalates) in the serum of thelarche patients but not controls. However there was no statistically significant correlation between phthalate exposure and thelarche.

In vitro sperm cultures (from 'normal' men) were exposed to various concentrations of phthalates (including DMP), for up to 18 h. Exposure to each of the phthalates including DMP resulted in a dose-dependent reduction in sperm velocity and straight-line motion (Fredricsson et al., 1993).

Data not reported in previous evaluations

Breast milk samples were analysed for 6 different phthalate monoesters in a Danish-Finnish cohort study on cryptorchidism, gonadotropins, sex-hormone binding globulin, testosterone and inhibin B. (Main et al., 2006). No association was found between MMP and cryptorchidism. MMP showed positive correlations with LH:free testosterone ratio.

Association between 11 maternal urinary phthalate monoester concentrations and genital parameters such as anogenital index (AGI) [anogenital distance (AGD) normalised for body weight] and testicular descent in children was investigated in 85 mother-son pairs (Swan et al., 2005). There was no significant association between maternal urinary MMP concentration and infant AGI.

Duty et al. (2003a; b) examined the levels of phthalate monoesters in urine of men attending an andrology clinic and also examined their semen quality and DNA damage in sperm. Eight urinary phthalate monoesters including MMP were measured in a single spot urine sample collected on the same day as the semen sample. There was no dose-response relation between MMP and sperm or semen parameters, and urinary MMP levels were not associated with increased sperm DNA damage (as measured by comet assay).

4.8.2 Repeat dose toxicity studies

Previous evaluations

Although no overt effects have been found in testes, DMP has been shown to significantly decrease testosterone levels in the serum and testes in rats after DMP was administered in diet at 2% (approximately 2000 mg/kg bw/d) to young male rats

for 7 days (Oishi & Hiraga, 1980). The effect on reproductive performance was not studied.

4.8.3 Prenatal developmental toxicity studies

Previous evaluations

Exposure of Sprague-Dawley dams (25-32 animals/dose), from gestational day (GD) 6-15, to concentrations of 0, 0.25, 1.0 and 5.0% DMP in feed (0, 200, 840 and 3570 mg/kg bw/d), resulted in reduced maternal food consumption with consequential loss of body weight gain in the high dose group. Relative liver weight was also increased in the high dose group. The NOAEL for maternal toxicity was determined at 840 mg/kg bw/d. No DMP-related effects (at any dose level) were observed on embryo/foetal development, including body weight and incidence of external, visceral and skeletal malformations (Field et al., 1993).

DMP (3500 mg/kg bw/d) administered by gavage to pregnant CD-1 mice (36 animals) from GD 7 - 15, did not elicit any signs of maternal toxicity or changes in body weight gain. No DMP-related effects were observed on foetal survival, litter size, litter weight or development (Plasterer et al., 1985).

Apart from a statistically significant reduction in body weight gain in the maternal high dose group, no evidence of maternal toxicity or developmental effects (gross, skeletal or visceral anomalies) was seen following dermal application of DMP at doses of 0, 0.5, 1.0 and 2.0 mL/d (applied by occluded dressing for 2 h/d) to Wistar rats (15-25 animals/dose) on GD 6-15 or GD 1-20 (Hansen & Meyer, 1989). There was no effect on numbers of implantations, corpora lutea or resorptions.

A developmental study was undertaken in Sprague-Dawley rats (5 females per dose) with 8 phthalate esters (including DMP) (Singh et al., 1972). DMP was administered by ip injection on GD 5, 10 and 15 at doses of 0.338, 0.675 and 1.125 mL/kg bw/d (approximately 400, 800 and 1340 mg/kg bw/d). Untreated animals or animals treated with normal saline or cottonseed oil (at 5 and 10 mL/kg bw) comprised the control groups. Animals were sacrificed and examined on GD 20. There was no effect on the number of corpora lutea. An increased number of resorptions was seen in both low and high dose but not in the intermediate dose. Numbers of dead foetuses increased in a dose-related trend with 9% foetal deaths at the highest dose. Foetal weights were significantly reduced (not dose related) in all dose groups. The frequencies of skeletal malformations were 25, 35 and 75% at low to high doses respectively, compared to 11% in controls. Malformations included missing tails/tail bones and/or eyes, elongated and fused ribs and incomplete skull bones. No details were provided regarding maternal toxicity.

Data not reported in previous evaluations

Sprague-Dawley outbred CD rats were treated by gavage daily from GD 12 to GD 19 at 500 mg/kg DMP per day. Limited data were presented, however, AGD was not different to controls (Liu et al., 2005). Testes were isolated on GD 19 and DMP showed no significant effects on gene expression using a microarray analysis.

4.8.4 Developmental/postnatal toxicity studies

Previous evaluations

DMP administered by gavage to Sprague-Dawley dams (5 animals), at 750 mg/kg bw/d from GD 14 to postnatal day (PND) 3, did not elicit any effects on sexual differentiation in male offspring. Endpoints included testes weight, undescended testes, testicular testosterone production, anogenital distance, areola. Treatment did not induce overt maternal toxicity or have effects on litter size, pup weight or sex ratio (Gray et al., 2000).

Litter size and growth of pups up to PND 3 were unaffected by 3.5 or 5 g/kg bw/d gavage on GD 6-13 to mice despite 12/43 deaths among the dams in the high dose group (Hardin et al., 1987).

4.8.5 Mode of action

DMP had no binding affinity for the oestrogen receptor and failed to prevent estradiol binding in vitro in rat (NCTR:SDN) uteri or human oestrogen receptor α or β (Nakai et al., 1999; Toda et al., 2004; Blair et al., 2000). DMP tested negative in a yeast two-hybrid assay as evaluated by its ability to induce hormone (β -galactosidase) activity, relative to 17β -oestradiol induced activity (Nishihara et al., 2000). Similarly, DMP showed no oestrogenic activity in vitro in a recombinant yeast screen assay nor did it show any mitogenic activity in oestrogen responsive human breast cancer cells (MCF-7 assay) (Harris et al., 1997). At concentrations up to $400\mu\text{M}$, the monoester metabolite, MMP (main metabolite of DMP) did not affect estradiol production in cultured rat ovarian granulosa cells (Lovekamp & Davies, 2001). MMP induced detachment of germ cells from a Sertoli cell monolayer in vitro but was 10000 fold less potent than MEHP (Gray & Gangoli, 1986).

4.8.6 Conclusion

Effects on fertility

The human and laboratory animal data are insufficient to assess adequately the effects of DMP on fertility. DMP significantly decreased testosterone levels in the serum and testes in young male rats following administration in diet at 2% (approximately 2000 mg/kg bw/d) for 7 days (Oishi & Hiraga, 1980). Reproductive performance in these animals was not assessed.

Developmental effects

A single study (Singh et al., 1972) reports significant developmental effects from ip injection of DMP to rats. The foetuses were small, with an increased frequency of skeletal anomalies. No details of maternal effects were reported. All other studies (Plasterer et al., 1985; Hardin et al., 1987; Hansen & Meyer 1989; Field et al., 1993; Gray et al., 2000) have reported no effects from treatment by the oral or dermal route. The NOAEL for developmental effects in a rat feeding study was 3570 mg/kg bw/d (highest dose tested). The disparity in results may be due to pharmacokinetic differences. Dosing by the ip route will potentially expose the foetus to higher levels of the parent diester than oral ingestion where DMP is readily broken down to the monoester by esterases in the gastrointestinal tract and liver.

5. Hazard Characterisation

DMP is absorbed via the gastrointestinal tract and via the skin. Following absorption, DMP is distributed to multiple organs but rapidly cleared, with no accumulation. In rats over 7 days, approximately 6% per day of dermally applied DMP is absorbed and recovered in urine and faeces. In vitro, human epidermis is an order of magnitude less permeable to DMP than rat epidermis. Following oral administration in rats, the main DMP metabolites are the monoester (MMP) (78%) with free phthalic acid and unmetabolised DMP comprising the rest of the eliminated dose.

DMP is of low acute oral and dermal toxicity in rats, mice, rabbits and guinea pigs. Data are insufficient to determine the potential for inhalation toxicity.

DMP produces minimal skin irritant effects in animals and humans. It induces minimal eye irritation in rabbits. A single human case report noted eye irritation following contact with DMP. Available data from animals and humans suggests that DMP is not a skin sensitiser.

In repeat dose animal studies, the kidney appears to be the primary target organ, with effects on nervous system, lungs, liver and testes also reported. A NOAEL of 1000 mg/kg bw/d and a LOAEL of 2000 mg/kg bw/d based on reduced weight gains were determined in a 2-year feeding study in rats. A repeat dose NOAEL of 1200 mg/kg bw/d and a LOAEL of 2400 mg/kg bw/d based on nephritis seen at this dose and above were determined from a 90-day dermal study in rabbits.

DMP showed equivocal evidence in both in vitro and in vivo genotoxicity studies. Equivocal evidence exists for the mutagenic activity of DMP in *S. typhimurium* strains TA 100 and TA 1535. However, these were the only strains testing positive. Positive results were reported in vitro in hamster SCE but DMP tested negative in these cells for chromosomal aberrations. No effects were reported for chromatid aberrations in human leukocyte cultures. DMP tested positive in mouse lymphoma assays with metabolic activation, however, the authors interpreted these results as possible false positives. In vivo, equivocal results were reported for hepatocyte chromosome aberrations and negative results were reported for chromosome damage in bone marrow and in dominant lethal tests. Overall, based on all data available and on a weight-of-evidence basis, DMP is unlikely to be genotoxic.

A 2-year rat feeding study did not report any neoplastic endpoints at concentrations of DMP up to 4000 mg/kg bw/d, however, details of endpoints evaluated and organs studied were not available. A one-year initiation/promotion study with dermal applications of 3000 mg/kg bw/d DMP in mice showed no evidence of carcinogenic initiation/promotion potential. A single mammalian cell transformation assay was negative. Overall, data are inadequate to determine the carcinogenic potential of DMP.

The human and laboratory animal data are insufficient to assess adequately the effects of DMP on fertility. A single study reported effects on development from ip injection of DMP in rats. In contrast, other studies (oral and dermal) reported no effects. Data suggest that gestational exposure to DMP in rats or mice above doses likely to be maternally toxic are unlikely to have no developmental consequences. The NOAEL for developmental effects in a rat oral feeding study was 3570 mg/kg bw/d (highest dose tested).

Page intentionally blank for double-sided printing.

6. Human Health Hazard Summary Table

Phthalate	Acute Toxicity	Irritation & Sensitisation	Repeated Dose Toxicity	Genetic Toxicity	Carcinogenicity	Fertility	Developmental Toxicity
Dimethyl (DMP)	<p>Oral Rat: LD50 = 2860 – 10000 mg/kg bw</p> <p>Dermal Rat: LD50 = 38000 mg/kg bw</p> <p>Inhalation No data</p>	<p>Skin Irritation: ME</p> <p>Eye Irritation: ME</p> <p>Sensitisation: negative</p>	<p>Oral Rat: NOAEL = 1000 mg/kg bw/d.</p> <p>LOAEL = 2000 mg/kg bw/d: ↓ body weight gain.</p> <p>Dermal Rat: NOAEL = 1200 mg/kg bw/d.</p> <p>LOAEL = 2400 mg/kg bw/d: nephritis</p> <p>High doses: nephritis, ↑ liver weight; ↓ liver cholesterol and total lipids; liver damage</p>	<p><i>In vitro</i> Equivocal in bacterial mutation assays</p> <p>Positive in SCE assay</p> <p>Negative in chromosomal aberration tests</p> <p>Equivocal in a mouse lymphoma assay</p> <p><i>In vivo</i> Equivocal in chromosomal aberration tests</p> <p>Negative in SCE assay</p> <p>Negative in a dominant lethal assay</p>	<p><i>In vitro</i> Negative in mammalian cell transformation assay.</p> <p><i>In vivo</i> Mouse: Negative for initiation or promotion activity</p>	<p>Rat: Insufficient data</p>	<p>Developmental study Rat: NOAEL = 3570 mg/kg bw/d.</p> <p>LOAEL: NE (>3570 mg/kg bw/d)</p> <p>Maternal effects: Rat: NOAEL = 840 mg/kg bw/d</p> <p>LOAEL = 3570 mg/kg bw/d: ↑ liver weight; ↓ body weight gain</p>

ME – minimal effects; NE – not established; SCE – sister chromatid exchange

Page intentionally blank for double-sided printing.

References

- Agarwal DK, Lawrence WH, Nunez LJ, & Autian J (1985) Mutagenicity evaluation of phthalic acid esters and metabolites in *Salmonella typhimurium* cultures. *Journal of Toxicology and Environmental Health*, 16 (1): 61-9.
- Albro PW & Moore B (1974) Identification of the metabolites of simple phthalate diesters in rat urine. *J Chromatogr*, 94: 209-218.
- Aldyreva MV, Klimova, TS, Izjumova AS, & Timofeevskaja LA (1975) Effects of phthalate plasticisers on genetic function. *Gigiena truda i professional'nye zabolevanija*, 12: 25.
- Barber ED, Cifone M, Rundell J, Przygoda R, Astill BD, Moran E, Mulholland A, Robinson E, & Schneider B (2000) Results of the L5178Y mouse lymphoma assay and the Balb/3T3 cell in vitro transformation assay for 8 phthalate esters. *J. Applied Toxicol.*, 20: 69-80.
- Bell FP, Patt CS, Brundage B, Gillies P, & Phillips WA (1978) Studies on lipid biosynthesis and cholesterol content of liver and serum lipoproteins in rats fed various phthalate esters. *Lipids*, 13(1):66-74.
- BIBRA (1994) Toxicity profile – Dimethyl Phthalate. pp1-8. BIBRA Information Services.
- Blair RM, Fang H, Branham WS, Hass BS, Dial SL, Moland CL, Tong W, Shi L, Perkins R, & Sheehan DM (2000) The oestrogenic receptor relative binding affinities of 188 natural and xenochemicals: structural diversity of ligands. *Toxicol. Sci.*, 54: 138-153.
- Carpenter CP & Smyth HF (1946) Chemical burns of the rabbit cornea. *Am J Ophthalmol*, 29: 1363-1372.
- Cater BR, Cook MW, Gangolli SD, & Grasso P (1977) Studies on dibutyl phthalate-induced testicular atrophy in the rat: effect on zinc metabolism. *Toxicology & Applied Pharmacology*, 41(3): 609-18.
- CIR (2002) Scientific Literature Review: Dibutyl phthalate, dimethyl phthalate and diethyl phthalate, August 5, 2002. Washington DC, Cosmetic Ingredient Review.
- CIR (2003) Dibutyl phthalate, diethyl phthalate and dimethyl phthalate re-review summary. Feb 7, 2003. Cosmetic Ingredient Review. <http://www.cir-safety.org/alerts.shtml> (accessed December 2007).
- Colon A, Caro D, Bourdony CJ, & Rosario O (2000) Identification of phthalate esters in the serum of young Puerto Rican girls with premature breast development. *Environ Health Perspect*, 108: 895-900.
- Dow Chemical (1946) TSCAT OTS0206677, Doc ID 878214827, N, 09.10.1946
- Draize JH, Alvarez E, Whitesell MF, Woodward G, Hagan E, & Nelson AA (1948) Toxicological investigations of compounds proposed for use as insect repellents. *J Pharmacol Exp Ther*, 93: 26-39.
- Draize JH, Woodward G, & Calvary HO (1944) Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes. *J Pharmacol Exp Ther*, 82: 377-390.
- Dupont E.I De Nemours (1970) TSCAT 215032, Doc ID 878220373, S, 01.10.1970
- Dupont E.I De Nemours (1982) Human Patch Test – 16 Subjects. U.S. EPA/OPTS Public Files. TSCATS Document Number: 878220371. Record Number: 019075. OTS 84003A.

- Duty S, Silva M, Barr D, Brock J, Ryan L, Chen Z, Herrick R, Christiani D, & Hauser R (2003a) Phthalate Exposure and Human Semen Parameters. *Epidemiology*, 14: 269–277.
- Duty SM, Singh NP, Silva MJ, Barr DB, Brock JW, Ryan L, Herrick RF, Christiani DC, & Hauser R (2003b) The relationship between environmental exposures to phthalates and DNA damage in human sperm using the neutral comet assay. *Environmental Health Perspectives*, 111: 1164-1169.
- ECB (2000) IUCLID Dataset Dimethyl Phthalate. European Commission - European Chemicals Bureau. 18 February 2000.
- Elsisi AE, Carter DE, & Sipes G (1989) Dermal absorption of phthalate diesters in rats. *Fund Appl Toxicol*, 12: 70-77.
- Field EA, Price CJ, Sleet RB, George JD, Marr MC, Myers CB, Schwetz BA, & Morrissey RE (1993) Developmental toxicity evaluation of diethyl and dimethyl phthalate in rats. *Teratology*, 48 (1): 33-44.
- Foster PM, Thomas LV, Cook MW, & Gangolli SD (1980) Study of the testicular effects and changes in zinc excretion produced by some n-alkyl phthalates in the rat. *Toxicology & Applied Pharmacology*, 54(3): 392-8.
- Fredricsson B; Moller L, Pousette A, & Westerholm R (1993) Human sperm motility is affected by plasticizers and diesel particle extracts. *Pharmacology and Toxicology*, 72(2): 128-133.
- Frosch PJ & Kligman AM (1977) Method for appraising the stinging capacity of topically applied substances. *J Soc Cosmet Chem*, 28: 197-209.
- Gangolli SD (1982) Testicular effects of phthalate esters. *Environmental Health Perspectives*, 45: 77-84.
- Gray TJB & Gangolli SD (1986) Aspects of the testicular toxicity of phthalate esters. *Environ Health Perspect*, 65: 229–235.
- Gray LE, Ostby J, Furr J, Price M, Veeramachaneni DN, & Parks L (2000) Perinatal exposure to the phthalates DEHP, BBP, and DINP, but not DEP, DMP, or DOTP, alters sexual differentiation of the male rat. *Toxicol Sci.*, 58 (2): 350-65.
- Hansen E & Meyer O (1989) No embryotoxic or teratogenic effect of dimethyl phthalate in rats after epicutaneous application. *Pharmacology and Toxicology*, 64(2): 237-238.
- Hardin BD, Schuler RL, Burg JR, Booth GM, Hazelden KP, Mackenzie KM, Piccirillo VJ, & Smith KN (1987) Evaluation of 60 chemicals in a preliminary developmental toxicity test. *Teratog Carcinog Mutagen*, 7: 29-48.
- Harris CA, Henttu P, Parker MG, & Sumpter JP (1997) The oestrogenic activity of phthalate esters in vitro. *Environmental Health Perspectives*, 105 (8): 802-811.
- Hilton J, Woollen BH, Scott RC, Auton TR, Trebilock KL, & Wilks MF (1994) Vehicle effects on in vitro percutaneous absorption through rat and human skin. *Pharmaceutical Research*, 11(10): 1396-1400.
- IPCS (2005) International Chemical Safety Card 0261. Dimethyl phthalate. International Programme on Chemical Safety/Commission of the European Communities. October 2005.
- Kanerva L, Jolanki R, Alanko K, & Estlander T (1999) Patch-test reactions to plastic and glue allergens. *Acta Dermato-Venereologica*, 79(4): 296-300
- Karel L, Landing B and Harvey T (1947) The intraperitoneal toxicity of some glycols, glycol ethers, glycol esters and phthalates in mice. *Fed. Proc.*, 6:342

- Kozumbo WJ & Rubin RJ (1991) Mutagenicity and metabolism of dimethyl phthalate and its binding to epidermal and hepatic macromolecules. *J Toxicol Environ Health*, 33(1): 29-46.
- Kozumbo WJ, Kroll R, & Rubin RJ (1982) Assessment of the mutagenicity of phthalate esters. *Environ Health Perspect.*, 45: 103-109.
- Kubo T, Urano K, & Utsumi H (2002) Mutagenicity characteristics of 255 environmental chemicals. *Journal of Health Science*, 48(6): 545-554.
- Lake BG et al. (1978) Abstract 215. 19th Annual Meeting of the Society of Toxicology, Washington DC.
- Lawrence WH, Malik M, Turner JE, Singh AR, & Autian J (1975) Toxicological investigation of some acute, short-term and chronic effects of administering di-2-ethylhexyl phthalate (DEHP) and other phthalate esters. *Environ Res*, 9: 1-11.
- Lehman AJ (1955) Insect repellants. *Assoc. Food and Drug Officials US Quart Bull*, 19: 87-99.
- Levinskas GJ (1973) Inhalation toxicity tests. *Techn. Pap. Reg. Tec. Conf.* p95-100 Soc. Plastics Engineers Inc.
- Liu K, Lehmann KP, Madhabananda S, Young SS, & Gaido KW (2005) Gene expression profiling following in utero exposure to phthalate esters reveals new gene targets in the etiology of testicular dysgenesis. *Biology of Reproduction*, 73: 180-192.
- Lovekamp TN & Davis BJ (2001) Mono-(2-ethylhexyl) phthalate suppresses aromatase transcript levels and estradiol production in cultured rat granulosa cells. *Toxicol. Appl. Pharmacol.*, 172: 217-224.
- Main KM, Mortensen GK, Kaleva MM, Boisen KA, Damgaard IN, Chellakooty M, Schmidt IM, Suomi AM, Virtanen HE, Petersen JH, Andersson AM, Toppari J, & Skakkebaek NE (2006) Human breast milk contamination with phthalates and alterations of endogenous reproductive hormones in infants three months of age. *Environmental Health Perspectives*, 114(2): 270-276.
- McLaughlin RS (1946) *Am J Ophthal*, 29:1355.
- Nakai M, Tabira Y, Asai D, Yakabe Y, Shimyozu T, Noguchi M, Takatsuki M, & Shimohigashi Y (1999) Binding characteristics of dialkyl phthalates for the oestrogen receptor. *Biochem Biophys Res Comm*, 254: 311-314.
- NICNAS (2008) Phthalate hazard compendium: a summary of physicochemical and human health hazard data for 24 *ortho*-phthalate chemicals. Sydney, National Industrial Chemicals Notification and Assessment Scheme.
- Nishihara T, Nishikawa J, Kanayama T, Dakeyama F, Saito K, Imagawa M, Takatori S, Kitagawa Y, Hori S, & Utsumi H (2000) Oestrogenic activities of 517 chemicals by yeast two-hybrid assay. *Journal of Health Science*, 46 (4): 282-298.
- NTP (1995) National Toxicology Program. Toxicology and carcinogenesis studies of diethylphthalate (CAS No. 84-66-2) in F344/N Rats and B6C3F1 mice (dermal studies) with dermal Initiation/ promotion study of diethylphthalate and dimethylphthalate (CAS No. 131-11-3) in male Swiss (CD-1(R)) mice. *Natl Toxicol Program Tech Rep Series*. Issue 429.
- OCS (2000) Office of Chemical Safety, Australian Government Department of Health and Ageing. Evaluation report on diethyltoluamide, dimethylphthalate. (Sep 2000). CPAS Submission No: 11887, 11910.
- Oishi S & Hiraga K (1980) Testicular atrophy induced by phthalic acid esters: effect on testosterone and zinc concentrations. *Toxicology and Applied Pharmacology*, 53: 35-41

- Oliwiecki S Beck MH, & Chalmers RJ (1991) Contact dermatitis from spectacle frames and hearing aid containing diethyl phthalate. *Contact Dermatitis*, 25: 264-265.
- Plasterer MR, Bradshaw WS, Booth GM, Carter MW, Schuler RL, & Hardin BD (1985) Developmental toxicity of 9 selected compounds following prenatal exposure in the mouse. *J Toxicol Environ Health*, 15 (1): 25-38.
- Reifenrath WG, Hawkins GS, & Kurtz MS (1989) Evaporation and skin penetration characteristics of mosquito repellent formulations. *J Am Mosquito Control Assoc.*, 5: 45-51.
- Schulsinger C & Mollgaard K (1980) Polyvinyl chloride dermatitis not caused by phthalates. *Contact Dermatitis*, 6: 133-144.
- Scott RC, Dugard PH, Ramsey JD, & Rhodes C (1987) In vitro absorption of some o-phthalate diesters through human and rat skin. *Environmental Health Perspectives*, 74: 223-228.
- Seed JL (1982) Mutagenic activity of phthalate esters in bacterial liquid suspension assays. *Environmental Health Perspectives*, 45: 111-114.
- Singh AR, Lawrence WH, & Autian J (1972) Teratogenicity of phthalate esters in rats. *Journal of Pharmaceutical Sciences*, 61: 51-55.
- Surina TY, Gleiberman SE, & Nikolaev GM (1984) Metabolism of dimethyl phthalate after cutaneous application. *Meditinskaya Parazitologiya i Parazitarnye Bolezni*, 4: 67-71.
- Takenaka T et al. (1970) Fundamental study of the safety of perfumes for cosmetics. Provocation of primary cutaneous irritation. *Parfum Cosmet Savons*, 13: 699.
- Timofievskaya LA et al. (1976) In: Major problems of remote after-effects of exposure to occupational poisons. Collected scientific works (Plyasunov AK & Pashkova M (eds) 40-43.
- Timofievskaya LA, Aldyreva, MV, & Kazbekov IM (1974) Experimental studies on the effect of phthalate plasticisers on the organism. *Gigiena i sanitarija*, 12: 26-28.
- Toda C, Okamoto Y, Ueda K, Hashizume K, Itoh K, & Kojima N (2004) Unequivocal oestrogen receptor-binding affinity of phthalate esters featured with ring hydroxylation and proper alkyl chain size. *Archives of Biochemistry and Biophysics*, 431: 16-21.
- Tsuchiya K & Hattori K (1976) Chromosomal study on human leukocyte cultures treated with phthalic acid esters. *Hokkaidoritsu Eisei Kenkyusho Ho.*, 26:114.
- Union Carbide Corporation (1987) TSCAT OTS0533903, Doc ID 88-920000746, 8ECP
- White PD, Carter DE, Earnest D, & Mueller J (1980) Absorption and metabolism of three phthalate diesters by the rat small intestine. *Food Cosmet Toxicol*, 18: 383-386.
- Yurchenko VV (1977) Cytogenetic investigation of mutagenic properties common to the repellents dimethylphthalate and N,N-diethylamide of phenoxyacetic acid. *Farmacol Toksikol.* 40: 454-457

Appendix - Robust Study Summaries

Reproductive toxicity

Test substance	DEHP, BBP, DEP, DINP, DMP and DOTP
Species	Sprague-Dawley rats, age-90 days, Source-Charles River Breeding Laboratory, Raleigh, NC.
Route of admin.	Oral
Exposure period	GD 14 to PND 3
Study Duration	Onset of gestation to postnatal days 90-150
Frequency of treatment	Daily
Doses	0, 0.75 g/kg bw/d
Control group	Corn oil vehicle
NOAEL maternal tox.	Nil
NOAEL teratogen.	Nil
Guidelines	Not mentioned
GLP	Not mentioned
Method	<p>Pregnant dams were dosed orally with each of DEHP, BBP, DEP, DINP, DMP and DOTP at 0.75 g/kg bw/d in corn oil, from GD 14 to PND 3 (5-10 animals per group)</p> <p>Offspring body weight and anogenital distance (AGD) were recorded on PND 2 and one male pup/litter (randomly selected) was necropsied to measure testes weight. At PND 9-10, male pups were examined for haemorrhagic testes and at PND 13 for nipple retention. Male pups were weaned on PND 28 and divided into groups of 2-3. Offspring were necropsied at 3-5 months of age.</p>
Result	<p>No treatment-related maternal toxicity or reductions in litter size were seen. DEHP caused reduced maternal body weight gain (ca. 15g). DEHP and DINP significantly reduced pregnancy weight gain to GD 21, by 23% 14% respectively. DEHP and BBP caused significantly reduced live pup weight (ca. 15%). DMP, DEP and DOTP did not cause maternal toxicity or reduce litter size.</p> <p>DEHP and BBP caused reduced AGDs (ca. 30%) and reduced testes weights (ca. 35%) in male pups. DEHP, BBP and DINP caused significantly higher nipple retention (87%, 70% and 22%, respectively) and significant induction of reproductive malformations in males (82%, 84%, 7.7 respectively). DEHP and BBP caused testes retention and sex organ toxicity (agenesis of the bulbourethral glands, ventral prostate and seminal vesicles, and phallus clefting). DMP, DEP and DOTP did not appear to cause reproductive malformations or sex organ toxicity in male offspring.</p>
Conclusion	BBP and DEHP significantly impaired sexual differentiation at 0.75 g/kg bw/d and also caused severe sex organ toxicity. DINP also impaired sexual differentiation to a lesser extent. DEP, DMP and DOTP were not developmental toxicants at this dose.
Reference	Gray LEJ, Ostby J, Furr J, Price M, Veeramachaneni D, & Parks L (2000) Perinatal exposure to the phthalates DEHP, BBP, and DINP, but not DEP, DMP, or DOTP, alters sexual differentiation of the male rat. <i>Toxicological Sciences</i> , 58: 350-365.